BGG announces an additional Novel Food approval for AstaZine
BGG and its subsidiary Algae Health Sciences (AlgaeHealth) announced today that their flagship product, AstaZine Natural Astaxanthin, has won an additional Novel Food approval from the Food Safety Authority of Ireland.
This new regulatory achievement is for BGG’s “Made-in-Europe” supercritically extracted Haematococcus pluvialis Flotow oleoresin products.
“We are extremely happy to offer Astaxanthin in two different grades including our premium supercritical CO2, solvent-free extraction line as well as our ethanol-extracted line, both now with full regulatory approval in the EU,” said Christian Artaria, CEO of BGG’s European operations and CMO for the BGG Group.
“This is yet another regulatory accomplishment in a quickly escalating list that includes innovations such as the first NDI for Astaxanthin greater than 12mg per day dosage.”
BGG is now the first company to have European Novel Food approval for both supercritical and ethanol extracts.
“Our goal is to give our customers a variety of options, innovative opportunities, and worldwide marketing reach including the most important regulated markets in our sector such as the USA, Europe, Japan and Australia,” said Bob Capelli, Algae Health Sciences Executive Vice President Global Marketing.
